CAS.NO: 1169630-82-3
Cat.No：P806
Storage conditions: -15℃ below, protected from light, sealed
Semaglutide Intermediate 29 Peptide, also known as Semaglutide 29 peptide main chain, Semaglutide Intermediate P29 or GLP-1(9-37), is the key intermediate of the synthesis of Semaglutide API.
| Items | Characteristic |
| Source | E.Coli |
| Appearances | White or off-white lyophilized powder |
| Solubility | Soluble in water (pH11.0-pH11.5) |
| Purity | ≥90.0% |
| Loss on drying | ≤10.0% |
| Content | Calculated on a dry basis, the content of semaglutide intermediate 29 peptide should be ≥ 90.0% |
The data should be subject to test report of products.
Semaglutide Intermediate 29 Peptide, also known as Semaglutide 29 peptide backbone, Semaglutide Intermediate P29 or GLP-1(9-37), is the key intermediate of the synthesis of Semaglutide API.
Semaglutide is a 2nd Generation GLP-1RA drug. In Dec., 2019, Semaglutide injection (brand name: Ozempic, 4mg/3ml) was approved by FDA to improve glycemic control in adults with type 2 diabetes. In Jun. 2021, Semaglutide injection (brand name Wegovy, 2.4mg/dose) was approved by FDA to treat obesity (BMI>30kg/m2) and overweight (BMI≥27kg/m2).
In Sep. 2019, oral Semaglutide (brand name, Rybelsus, 3ma, 7mg and 14ma/ tablet) was approved by FDA for the treatment of type 2 diabetes. Meanwhile, Rybelsus 25mg and 50mg strengths showed clear effects in Phase II and Phase III clinical trials for weight loss or non-alcoholic fatty liver (NASH). In Oct., 2023, phase II clinical trials for patients with insufficiency type II diabetes and chronic kidney disease were terminated early due to excellent efficacy.
Gene-Biocon Semaglutide intermediate P29 (GLP- 1(9-37)) is produced by genetic engineering fermentation. The production process is carried out under GMP conditions and the product purity is high. This product is a lyophilized powder obtained by enzyme cleavage, chromatography purification and freeze drying of the Semaglutide precursor expressed
by Escherichia coli. It has been supplied on a commercial scale and can be packaged and customized according to customer requirements.
Animal-free: no animal viruses, no pathogenic substances or exogenous factor contamination, highly safe.
Meet the requirements of GMP specification.
Complete quality documents.
For the production of Semaglutide.
Take an appropriate amount of this product and dissolve it in purified water to make the concentration of Semaglutide Intermediate P29 5-10mg/ml, adjust the pH to 11.0-11.5 to dissolve and clarify. Optimize the reaction system and synthesize Semaglutide.
Transportation stability: It is transported in an ice pack to keep it active.
Storage stability: It can be stored stably for 24 months at -15℃ or below in a sealed and dark place.
Avoid long time storage in liquid condition, please use it as soon as possible once it was dissolved.
Avoid strong acids, strong bases, strong oxidants, high concentrations of organic solvents and other reagents that can easily cause protein denaturation.
The product is for research and production only and should not be used for diagnosis or treatment of animals or humans.
